Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph) …

E Jabbour, J Cortes, F Giles, S O'Brien, L Letvak… - Blood, 2006 - Elsevier
Nilotinib is a novel, highly selective oral Bcr-Abl inhibitor which is approximately 30-fold
more potent than imatinib. High response rates with nilotinib were observed in all CML …
被引用次数：12 相关文章

Preliminary Activity of Nilotinib (AMN107), a Novel Selective Potent Oral Bcr-Abl Tyrosine Kinase Inhibitor, in Newly Diagnosed Philadelphia Chromosome (Ph) …

E Jabbour, J Cortes, F Giles, S O'Brien, L Letvak… - 2006 - ashpublications.org
Nilotinib is a novel, highly selective oral Bcr-Abl inhibitor which is approximately 30-fold
more potent than imatinib. High response rates with nilotinib were observed in all CML …